Indication (pathologie):
Cancer du poumon à grandes cellules
Identifiant SNOMED-CT:
SCTID: 254637007
Etudes cliniques
-
A phase 3, open label, randomised, multi-centre, international study of MEDI4736, versus standard of care in patients with locally advanced or metastatic non-small cell lung cancer (stage IIIB-IV) who have received at least two prior systemic treatment regimens including one platinum-based chemotherapy regimen and do not have known EGFR TK activating mutations or ALK rearrangements (ARCTIC)Phase de l'étude: Phase IIIRecrutement: Fermé
-
A double-blind, placebo controlled, multicentre, clinical Trial to investigate the efficacy and safety of 12 months of therapy with inhaled PROMIXIN® (colistimethate sodium) in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)”Indication (pathologie):Fibrose non kystique (bronchectasie)Identifiant SNOMED-CT:12295008Indication (pathologie):Infection due au Pseudomonas aeruginosaIdentifiant SNOMED-CT:11218009Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A randomized, blinded, parallel group, multi-center dose- finding study, to assess the efficacy, safety and tolerability of different doses of Tobramycin inhalation powder in patients with Non-Cystic Fibrosis Bronchiectasis and pulmonary P. aeruginosa infectionIndication (pathologie):BronchectasieIdentifiant SNOMED-CT:12295008Indication (pathologie):Infection due au Pseudomonas aeruginosaIdentifiant SNOMED-CT:11218009Phase de l'étude: Phase IIRecrutement: Ouvert
-
A phase IIb, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and intermediate or high probability of group 3 pulmonary hypertension.Indication (pathologie):Fibrose pulmonaire idiopathique (FPI)Identifiant SNOMED-CT:700250006Indication (pathologie):Hypertension pulmonaireIdentifiant SNOMED-CT:70995007Phase de l'étude: Phase IIRecrutement: Ouvert
-
A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairmentIndication (pathologie):Fibrose pulmonaire idiopathique (FPI)Identifiant SNOMED-CT:700250006Phase de l'étude: Phase IIIRecrutement: Fermé
-
A 12-week, double-blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment.Indication (pathologie):Fibrose pulmonaire idiopathique (FPI)Identifiant SNOMED-CT:700250006Indication (pathologie):Capacité de force vitale (CVF)Identifiant SNOMED-CT:50834005Phase de l'étude: Phase IVRecrutement: Fermé
-
Un registre prospectif d'observation pour décrire l'évolution de la maladie et les résultats cliniques chez les patients atteints de fibrose pulmonaire idiopathique dans un environnement clinique réelIndication (pathologie):Fibrose pulmonaire idiopathiqueIdentifiant SNOMED-CT:700250006Recrutement: Ouvert
-
Facteurs prédictifs du rejet chronique chez le transplanté pulmonaire : Etude COLT. Etude de physiopathologie, prospective, nationale, multicentrique en ouvertIndication (pathologie):Rejet chronique de la transplantation pulmonaireIdentifiant SNOMED-CT:432958009Recrutement: Fermé
-
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with progressive fibrosing interstitial lung disease (PF-ILD)Indication (pathologie):Maladie pulmonaire interstitielleIdentifiant SNOMED-CT:233703007Phase de l'étude: Phase IIIRecrutement: Fermé
-
A Randomized, double-blind, parallel group, multi-center study to assess the efficacy and safety of PT009 compared to PT005 on COPD exacerbations over a 52-week treatment period in subjects with moderate to very severe COPDIndication (pathologie):Maladie pulmonaire obstructive chronique (MPOC)Identifiant SNOMED-CT:13645005Phase de l'étude: Phase IIIRecrutement: Fermé
-
A multicenter, randomized, 52-week, double-blind, parallel-group, active controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthmaIndication (pathologie):AsthmeIdentifiant SNOMED-CT:195967001Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A prospective, single arm, longitudinal cohort study to assess biomarkers in real world patients with severe asthmaIndication (pathologie):Asthme sévèreIdentifiant SNOMED-CT:370221004Recrutement: Fermé
-
Colistin use in cystic fibrosis patients: Pharmacokinetic studies (intravenous administration) in relation with pharmacodynamics, tolerance profile and risk of selection of resistance. A multicenter prospective studyIndication (pathologie):MucoviscidoseIdentifiant SNOMED-CT:190905008Recrutement: Ouvert
-
Etude des altérations de la voie de l’adiponectine induites par l’hypoxémie chez le patient BPCOIndication (pathologie):Bronchopneumopathie chronique obstructive (BPCO)Identifiant SNOMED-CT:13645005Recrutement: Ouvert
-
Non-invasive detection of chronic pulmonary graft dysfunction: prospective longitudinal studyRecrutement: Ouvert
-
A multicentric prospective study to assess the safety and the usefulness of transbronchial lung cryobiopsies (TBLC) in patients with interstitial lung diseasesIndication (pathologie):Maladie pulmonaire interstitielleIdentifiant SNOMED-CT:233703007Recrutement: Ouvert
-
Origine et pathogénèse de la production de monoxyde d'azote exhalé chez le patient allergiqueIndication (pathologie):AllergieIdentifiant SNOMED-CT:473011001